Drug Profile
Solid tumour immunotherapy - Genentech
Alternative Names: Tumor Immunotherapy MAb - GenentechLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Genentech
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (Parenteral)
- 20 Sep 2011 Phase-I clinical trials in Solid tumours in USA (Parenteral)